Vimarsana
Biggest News Aggregation in the World

Michael Ropacki News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Michael Ropacki. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Michael Ropacki Today - Breaking & Trending Today

ORYZON Announces Topline Results from Phase IIb PORTICO - Vimarsana News

ORYZON Announces Topline Results from Phase IIb PORTICO

Company to host Conference Call and live Webcast on Sunday, January 7, 2024 at 5:30 pm PT. An executive summary of the data to be presented at the 7th...

ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD) - Vimarsana News

ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)

Company to host Conference Call and live Webcast on Sunday, January 7, 2024 at 5:30 pm PT.An executive summary of the data to be presented at the ...

ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for Borderline Personality Disorder (BPD) - Vimarsana News

ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for Borderline Personality Disorder (BPD)

Company on track to report top line data milestone in 1Q 2024A total of 210 participants have been recruitedMultiple primary endpoints include reduction in agitation and aggression and overall BPD disease improvement MADRID, Spain and BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today announced Last Patient Last Vi

Source: yahoo.com
ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for Borderline Personality Disorder (BPD) - Vimarsana News

ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for Borderline Personality Disorder (BPD)

Company on track to report top line data milestone in 1Q 2024A total of 210 participants have been recruitedMultiple primary endpoints include reduction in agitation and aggression and overall BPD...

ORYZON presents blinded aggregate safety data from vafidemstat's ongoing Phase IIb PORTICO trial in Borderline Personality Disorder - Vimarsana News

ORYZON presents blinded aggregate safety data from vafidemstat's ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

At the 36th European College of Neuropsychopharmacology congress (ECNP-2023)MADRID, Spain and BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Oryzon G...